GYPA

Glycophorin-A · P02724 · GYPA on Sugi Atlas →

11 patent compounds predicted against GYPA, 6 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL10565538 SCHEMBL10565538 0.45 1/20
SCHEMBL10803799 SCHEMBL10803799 0.42 1/20
SCHEMBL10809088 SCHEMBL10809088 0.42 1/20
SCHEMBL8644844 SCHEMBL8644844 0.41 1/20
SCHEMBL9799958 SCHEMBL9799958 0.41 1/20
SCHEMBL10807993 SCHEMBL10807993 0.40 1/20

Clinical trials — most relevant to GYPA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects PHASE4COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses PHASE2COMPLETED
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity PHASE2COMPLETED
Erythropoietin Therapy for Subarachnoid Hemorrhage PHASE2COMPLETED
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) PHASE2COMPLETED
High-Dose Ambroxol in GBA1-Related Parkinson PHASE1/PHASE2UNKNOWN
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) PHASE1/PHASE2RECRUITING
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia PHASE1COMPLETED
Study of Blood Samples From Newborns With Down Syndrome nanCOMPLETED
The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) nanCOMPLETED
OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis nanUNKNOWN
The Natural History of Sialidosis Type I nanRECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) nanCOMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome nanCOMPLETED
Perioperative Plasma Levels of Glycocalyx Markers in Colon Surgery. nanUNKNOWN
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases nanCOMPLETED
Glycans Bound to Serum Haptoglobin: a Novel Gastric Cancer Tumor Biomarker nanCOMPLETED
Clinical Trial Readiness for the Dystroglycanopathies nanRECRUITING
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors nanNOT_YET_RECRUITING
Role and Expression of MXRA5 in Placental Connective Tissue Remodelling in Preeclampsia nanUNKNOWN
A Real-world, Multi-center, Prospective, Observational Study for PNH in China nanCOMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain nanCOMPLETED
The MyoThrombus Study nanCOMPLETED
Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria nanCOMPLETED
Registry Gangliosidoses nanUNKNOWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GYPA binder may also engage these)

ProteinNameSimilarity
Q28913 1.000 Q28913 →
P14221 1.000 P14221 →
P02727 0.996 P02727 →
Q28914 0.994 Q28914 →
Q77NN4 0.994 Q77NN4 →
F5HGU6 0.994 F5HGU6 →
P09258 0.994 P09258 →
Q2LCV6 0.993 Q2LCV6 →
P02725 0.992 P02725 →
P16744 0.992 P16744 →
Q03345 0.991 Q03345 →
P14220 0.991 P14220 →
A6NHS7 0.991 A6NHS7 →
Q8VD58 0.991 Q8VD58 →
Q5RBQ2 0.991 Q5RBQ2 →
A0A1B0GWG4 0.990 A0A1B0GWG4 →
P69339 0.990 P69339 →
P69338 0.990 P69338 →
Q5RII3 0.989 Q5RII3 →
Q90YM4 0.989 Q90YM4 →
Q69569 0.989 Q69569 →
Q9D2S4 0.989 Q9D2S4 →
P68329 0.989 P68329 →
Q95M19 0.989 Q95M19 →
F5HB98 0.988 F5HB98 →
P35767 0.988 P35767 →
Q68FB2 0.988 Q68FB2 →
P35768 0.988 P35768 →
Q9D9V2 0.988 Q9D9V2 →
Q9Y5Y7 0.988 Q9Y5Y7 →